Vildagliptin (Galvus) — Competitive Intelligence Brief

Vildagliptin (Galvus) (Vildagliptin (Galvus)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule

Target snapshot

Vildagliptin (Galvus) (Vildagliptin (Galvus)) — University Hospital, Strasbourg, France. Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vildagliptin (Galvus) TARGET	Vildagliptin (Galvus)	University Hospital, Strasbourg, France	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Galvus (vildagliptin)	Galvus (vildagliptin)	Korea University Anam Hospital	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
alogliptin and actoplus met	alogliptin and actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
CSII+Vildagliptin	CSII+Vildagliptin	The First Affiliated Hospital of Xiamen University	marketed	DPP-4 inhibitor (combined with insulin therapy)	DPP-4 (dipeptidyl peptidase-4)
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class